IRA Impact On Biopharma R&D Bears Watching, US FDA’s Cavazzoni Says

The head of the US FDA’s drug center suggests that economic factors, including the Inflation Reduction Act, are potentially more important pathways shaping the focus of research and development than regulatory flexibility.